Merck Releases Positive Study For Vytorin, But How Much Impact Will It Have?
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Merck & Co. is ready to move forward with a new submission for Vytorin for treatment of chronic kidney disease patients, having finally gathered positive study results for a cholesterol-lowering drug in the high-risk patient population.
You may also be interested in...
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Zafgen Drops Beloranib, But Its New Focus Raises Doubts
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.
Update: Ziopharm Study Death Not Due To Drug
The biotech confirmed that a recent death during a clinical trial was not caused by its early-stage gene therapy.